Abstract
Heart failure (HF) has high morbidity and mortality in children. This study aimed to investigate the value of cardiac myosin binding protein-C (cMyBP-C) as a diagnostic and prognostic biomarker in children with heart failure. This study was a prospective case–control study that involved 50 children with acute HF and 25 healthy children of matched age and sex as a control group. cMyBP-C plasma levels were measured in patients with HF at the time of admission and 1 month after treatment. Echocardiographic assessment was done for all children. All patients were followed up for a period of 3 months. There was a significant increase in plasma levels of cMyBP-C (ng/ml) in patients with HF at admission (122.44 ± 41.01) as compared to patients after treatment (71.38 ± 49.68) and to control group (24.40 ± 9.83). This increase was associated with increased severity of HF according to pediatric Ross classification of HF. Significant increase in plasma levels of cMyBP-C at admission and its persistent increase after treatment were associated with adverse outcome of mortality and readmission. Plasma levels of cMyBP-C were significantly correlated with echocardiographic and clinical assessment of heart failure. Plasma levels of cMyBP-C were a good biomarker for diagnosis of HF with sensitivity 100% and specificity 96% at cutoff point of 45 ng/ml. Its value in predicting adverse outcome in HF patients was obtained by ROC curve with sensitivity of 90% and specificity 93% at a cutoff point of 152 ng/ml cMyBP-C at admission. cMyBP-C may be a novel useful diagnostic and prognostic biomarker in children with heart failure and determination of severity of HF in these patients.
Similar content being viewed by others
References
Rossano JW, Kim JJ, Decker JA, Price JF, Zafar F, Graves DE, Morales DL et al (2012) Prevalence, morbidity and mortality of heart failure related hospitalization in children in the Unites States: a population based study. J Card Fail 18:459–470
Juenger J, Schellberg D, Kraemer S et al (2002) Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 87(3):235–241
Hickman PE, Potter JM (2003) New cardiac markers. Aust Prescr 26:88–90
Cohen-Solal A, Laribi S, Ishihara S, Vergaro G, Baudet M, Logeart D, Mebazaa A, Gayat E, Vodovar N, Pascual-Figal DA, Seronde MF (2015) Prognostic markers of acute decompensated heart failure: the emerging roles of cardiac biomarkers and prognostic scores. Arch Cardiovasc Dis 108:64–74
Copeland O, Sadayappan S, Messer AE, Steinen GJM, van der Velden J, Marston SB (2010) Analysis of cardiac myosin binding protein C phosphorylation in human heart muscle. J Mol Cell Cardiol 49(6):1003–1011
Barefield D, Sadayappan S (2010) Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol 48(5):866–875
El-Armouche A, Pohlmann L, Schlossarek S, Starbatty J, Yeh YH, Nattel S, Dobrev D, Eschenhagen T, Carrier L (2007) Decreased phosphorylation levels of cardiac myosin binding protein C in human and experimental heart failure. J Mol Cell Cardiol 43(223):229
Govindan S, Kuster DWD, Lin B, Jeske WP, Walenga JM, Leya F, Hoppensteadt D, Fareed J, Sadayappan S (2013) Increase in cardiac myosin binding protein C plasma levels is a sensitive and cardiac specific biomarker of myocardial infarction. Am J Cardiovasc Dis 3(2):60–70
Govindan S, McElligott A, Muthusamy S, Nair N, Barefield D, Martin JL, Gongora E, Greis KD, Luther PK, Winegrad S, Henderson KK, Sadayappan S (2012) Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J Mol Cell Cardiol 52(1):154–164
Ross RD, Daniels SR, Schwartz DC, Hannon DW, Shukla R, Kaplan S (1987) Plasma levels of norepinephrine in infants and children with congestive heart failure. Am J Cardiol 59:911–914
McMurray JJ (2010) Clinical practice. Systolic heart failure. N Engl J Med 362:228–238
Sato Y, Fujiwara H, Takatsu Y (2012) Biochemical markers in heart failure. J Cardiol 59(1):1–7
Jeong EM, Zhou L, Xie A, Liu M, Zhou A, Liu H, Liu D, Shi G, Dudley S (2015) Heart failure and cardiomyopathies. JACC 65(10S):993
Sadayappan S, Osinska H, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, Seidman CE, Seidman JC, Robbins J (2006) Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc Natl Acad Sci USA 103:16918–16923
Razzaque MA, Gupta M, Osinska H, Gulick J, Blaxall BC, Robbins J (2013) An endogenously fragment of the cardiac myosin-binding protein C is pathogenic and can lead to heart failure. Circ Res 113(5):553–561
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors have no potential conflict of interest to disclose.
Rights and permissions
About this article
Cite this article
El Amrousy, D., Hodeib, H., Suliman, G. et al. Diagnostic and Prognostic Value of Plasma Levels of Cardiac Myosin Binding Protein-C as a Novel Biomarker in Heart Failure. Pediatr Cardiol 38, 418–424 (2017). https://doi.org/10.1007/s00246-016-1532-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-016-1532-2